DocDollars

Novartis Gene Therapies, Inc. (Fka Avexis, Inc.)

IL · United States · Reporting entity ID 100000486816

Total reported 2019–2025
$11.5M
#453 of 2,960 reporting companies — 0% of all reported industry payments
$1.84M in general payments across 3,852 records, plus $9.67M in research funding across 1,559 records.

How it breaks down

General payments $1,836,735
Research funding $9,666,886

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Novartis Gene Therapies, Inc. (Fka Avexis, Inc.) reported $11.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #453 of 2,960 reporting companies. 84% of that was research funding and 16% general payments such as consulting, speaking, food and travel. 3,852 general payment records and 1,559 research records were filed.

Common questions about Novartis Gene Therapies, Inc. (Fka Avexis, Inc.)

How much has Novartis Gene Therapies, Inc. (Fka Avexis, Inc.) paid US doctors?

Novartis Gene Therapies, Inc. (Fka Avexis, Inc.) reported $11,503,622 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,836,735 in general payments, $9,666,886 in research funding.

How does Novartis Gene Therapies, Inc. (Fka Avexis, Inc.) rank among drug and device companies?

It ranks #453 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Novartis Gene Therapies, Inc. (Fka Avexis, Inc.) mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.